The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy - Takeaways - MDSpire

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

  • By

  • Raffaella Greco

  • Isabel Sánchez-Ortega

  • Antonio M. Risitano

  • Krzysztof Kalwak

  • Annalisa Ruggeri

  • Iliana Kleovoulou

  • Marina Atlija

  • Tobias Alexander

  • Emanuele Angelucci

  • Dina Averbuch

  • Ali Bazarbachi

  • Maria Ester Bernardo

  • Charles Crawley

  • Mette D. Hazenberg

  • Olaf Penack

  • Helen Baldomero

  • Jakob R. Passweg

  • Ibrahim Yakoub-Agha

  • Donal P. McLornan

  • Fabio Ciceri

  • Anna Sureda

  • May 27, 2026

  • 0 min

Share

  • 1

    In 2024, the EBMT reported over one million hematopoietic cell transplants (HCTs) since 1990, marking a significant milestone in cellular therapy.

  • 2

    The survey recorded 47,204 HCTs in 2024, with a slight overall decrease in activity but an increase in allogeneic transplants to the highest level to date.

  • 3

    CAR-T therapy expanded significantly, treating 6,082 patients in 2024, surpassing 20,000 therapies since 2018, with lymphomas as the leading indication.

  • 4

    The EBMT survey will begin separate reporting for adult and pediatric activities in 2025, enhancing the monitoring of trends and clinical needs.

  • 5

    The data collection process has evolved to include new disease categories and detailed reporting on CAR-T and gene therapy indications for improved accuracy.

Original Source(s)

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

  • by Raffaella Greco, Isabel Sánchez-Ortega, Antonio M. Risitano, Krzysztof Kalwak, Annalisa Ruggeri, Iliana Kleovoulou, Marina Atlija, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Maria Ester Bernardo, Charles Crawley, Mette D. Hazenberg, Olaf Penack, Helen Baldomero, Jakob R. Passweg, Ibrahim Yakoub-Agha, Donal P. McLornan, Fabio Ciceri, Anna Sureda

  • May 27, 2026

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer